Major findings included the accumulation of zymogen granules, vacuolation due to foci of cytoplasmic degradation, and alterations in the morphology of the zymogen granules (Figure2A)
Major findings included the accumulation of zymogen granules, vacuolation due to foci of cytoplasmic degradation, and alterations in the morphology of the zymogen granules (Figure2A). acute cholangitis or in cases where biliary stasis Tepoxalin is suspected, an early endoscopic retrograde cholangiopancreatography is recommended. However, practice guidelines regarding the treatment of pancreatitis are suboptimal. In chronic pancreatitis, conservative management strategies include lifestyle modifications and dietary changes followed by analgesics and pancreatic enzyme supplementation. Recently, attention has been focused on phytoceuticals or antioxidants as agents that could surpass the limitations associated with currently available therapies. Because oxidative stress has been shown to play an important role in the pathogenesis of pancreatitis, antioxidants alone or combined with conventional therapy may improve oxidative-stress-induced organ damage. Interest in phytoceuticals stems from their potential use as simple, accurate tools for pancreatitis prognostication that could replace older and more tedious methods. Therefore, the use of antioxidative nutrition or phytoceuticals may represent a new direction for clinical research in pancreatitis. In this review article, recent advances in the understanding of the pathogenesis of pancreatitis are discussed and the paradigm shift underway to develop phytoceuticals and antioxidants to treat it is introduced. Despite the promise of studies evaluating the effects of antioxidants/phytoceuticals in pancreatitis, translation to the clinic has thus far been disappointing. However, it is expected that continued research will provide solid evidence to justify the use of antioxidative phytoceuticals in the treatment of pancreatitis. Keywords:Acute pancreatitis, Chronic pancreatitis, Severe acute pancreatitis, Antioxidants, Phytoceuticals Core tip:In this Tepoxalin review, the paradigm shift regarding the development of phytoceuticals and antioxidants is introduced following a comprehensive description of newer information pertaining to the pathogenesis of pancreatitis. Several animal models are discussed with regard to their role in efforts to develop efficient strategies against pancreatitis. Subsequently, newer therapeutic options with an emphasis on nutrients and phytoceuticals are reviewed. Further discussion also focuses on the promise Rabbit Polyclonal to Cytochrome P450 2D6 of studies evaluating the effects of antioxidants/phytoceuticals in pancreatitis, the disappointing nature of translation of these agents to clinical settings, and the expected research advances that may support the use of antioxidative phytoceuticals in the treatment of pancreatitis. == INTRODUCTION == Acute pancreatitis (AP) is a relatively common clinical condition, presenting with variable severity from mild and self-limited attacks to severe attacks that contribute to mortality[1]. Severity is associated mechanistically with the underlying pathogenesis of AP which includes pancreatic acinar cell injury in early stages after a local inflammatory reaction, subsequent acinar cell death in the form of apoptosis and necrosis, and the initiation of systemic inflammatory response syndrome (SIRS). An excessive SIRS prospects to distant organ damage referred to as multiple organ dysfunction syndrome (MODS)[2]. Recent insights changed a paradigm shift in understanding of AP that intra-acinar trypsinogen activation might lead to early pancreatic injury, but the inflammatory response of AP evolves individually Tepoxalin driven by early activation of enzyme activation[3]. Whereas, though still effective, the concept the pancreatic injury is initiated within pancreatic acinar cells subsequent to premature intracellular activation of digestive enzymes and these zymogen activations within acini early during AP was shown to be adequate to induce AP, finally contributed to the development of chronic pancreatitis[4,5]. Recently, Sah et al[6] found that cerulean-induced chronic pancreatitis (CP) did not require intra-acinar activation of trypsinogen, whereas rules of the inflammatory response by nuclear element Tepoxalin kappa B (NF-B) might be involved in the pathogenesis of CP. Collectively, these data suggest a need for the development of novel compounds to either block the early activation of pancreatic enzymes or to ameliorate inflammation in order to limit or prevent complications of AP or inhibit the progression to CP or inflammation-associated fibrosis or carcinogenesis. The delay between the onset of pancreatitis and the development of the systemic response makes AP an ideal.
